<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:hpo ids='HP_0000135'>Hypogonadism</z:hpo> is the most common morbidity in patients with transfusion-dependent <z:hpo ids='HP_0001903'>anemias</z:hpo> such as <z:e sem="disease" ids="C0002875" disease_type="Disease or Syndrome" abbrv="">thalassemia major</z:e> </plain></SENT>
<SENT sid="1" pm="."><plain>We used magnetic resonance imaging (MRI) to measure pituitary R2 (iron) and volume to determine at what age these patients develop pituitary <z:e sem="disease" ids="C0282193" disease_type="Disease or Syndrome" abbrv="">iron overload</z:e> and volume loss </plain></SENT>
<SENT sid="2" pm="."><plain>We recruited 56 patients (47 with <z:e sem="disease" ids="C0002875" disease_type="Disease or Syndrome" abbrv="">thalassemia major</z:e>, five with chronically transfused <z:e sem="disease" ids="C0271979" disease_type="Disease or Syndrome" abbrv="">thalassemia intermedia</z:e> and four with <z:e sem="disease" ids="C1260899" disease_type="Disease or Syndrome" abbrv="BDS">Blackfan-Diamond syndrome</z:e>) to have pituitary MRIs to measure pituitary R2 and volume </plain></SENT>
<SENT sid="3" pm="."><plain><z:hpo ids='HP_0000135'>Hypogonadism</z:hpo> was defined clinically based on the timing of secondary sexual characteristics or the need for <z:chebi fb="25" ids="50112">sex hormone</z:chebi> replacement therapy </plain></SENT>
<SENT sid="4" pm="."><plain>Patients with transfusional <z:e sem="disease" ids="C0282193" disease_type="Disease or Syndrome" abbrv="">iron overload</z:e> begin to develop pituitary <z:e sem="disease" ids="C0282193" disease_type="Disease or Syndrome" abbrv="">iron overload</z:e> in the first decade of life; however, clinically significant volume loss was not observed until the second decade of life </plain></SENT>
<SENT sid="5" pm="."><plain>Severe pituitary <z:mpath ids='MPATH_41'>iron deposition</z:mpath> (Z &gt; 5) and volume loss (Z &lt; -2.5) were independently predictive of <z:hpo ids='HP_0000135'>hypogonadism</z:hpo> </plain></SENT>
<SENT sid="6" pm="."><plain>Pituitary R2 correlated significantly with serum ferritin as well as liver, pancreatic, and cardiac <z:mpath ids='MPATH_41'>iron deposition</z:mpath> by MRI </plain></SENT>
<SENT sid="7" pm="."><plain>Log pancreas R2* was the best single predictor for pituitary iron, with an area under the receiving operator characteristic curve of 0.88, but log cardiac R2* and ferritin were retained on multivariate regression with a combined r(2) of 0.71 </plain></SENT>
<SENT sid="8" pm="."><plain>Pituitary <z:e sem="disease" ids="C0282193" disease_type="Disease or Syndrome" abbrv="">iron overload</z:e> and volume loss were independently predictive of <z:hpo ids='HP_0000135'>hypogonadism</z:hpo> </plain></SENT>
<SENT sid="9" pm="."><plain>Many patients with moderate-to-severe pituitary <z:e sem="disease" ids="C0282193" disease_type="Disease or Syndrome" abbrv="">iron overload</z:e> retained <z:mpath ids='MPATH_458'>normal</z:mpath> gland volume and function, representing a potential therapeutic window </plain></SENT>
<SENT sid="10" pm="."><plain>The subset of hypogonadal patients having preserved gland volumes may also explain improvements in pituitary function observed following intensive chelation therapy </plain></SENT>
<SENT sid="11" pm="."><plain>Am </plain></SENT>
<SENT sid="12" pm="."><plain>J </plain></SENT>
<SENT sid="13" pm="."><plain>Hematol </plain></SENT>
<SENT sid="14" pm="."><plain>2011. Â© 2011 Wiley Periodicals, Inc </plain></SENT>
</text></document>